PL1771468T3 - Zasiedlające nowotwory komórki inżynierowane w celu wytwarzania ligandu czynnika martwicy nowotworu indukującego apoptozę (TRAIL) - Google Patents
Zasiedlające nowotwory komórki inżynierowane w celu wytwarzania ligandu czynnika martwicy nowotworu indukującego apoptozę (TRAIL)Info
- Publication number
- PL1771468T3 PL1771468T3 PL05764208T PL05764208T PL1771468T3 PL 1771468 T3 PL1771468 T3 PL 1771468T3 PL 05764208 T PL05764208 T PL 05764208T PL 05764208 T PL05764208 T PL 05764208T PL 1771468 T3 PL1771468 T3 PL 1771468T3
- Authority
- PL
- Poland
- Prior art keywords
- tumor
- necrosis factor
- ligand
- trail
- apoptosis
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 102000003390 tumor necrosis factor Human genes 0.000 title 1
- 108700012411 TNFSF10 Proteins 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 abstract 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4232—Tumor necrosis factors [TNF] or CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/49—Breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/48—Regulators of apoptosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04017907A EP1621550A1 (en) | 2004-07-29 | 2004-07-29 | Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) |
| PCT/EP2005/007957 WO2006010558A1 (en) | 2004-07-29 | 2005-07-21 | Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail) |
| EP05764208A EP1771468B1 (en) | 2004-07-29 | 2005-07-21 | Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1771468T3 true PL1771468T3 (pl) | 2010-07-30 |
Family
ID=34925971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05764208T PL1771468T3 (pl) | 2004-07-29 | 2005-07-21 | Zasiedlające nowotwory komórki inżynierowane w celu wytwarzania ligandu czynnika martwicy nowotworu indukującego apoptozę (TRAIL) |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20070264231A1 (enExample) |
| EP (2) | EP1621550A1 (enExample) |
| JP (1) | JP5042826B2 (enExample) |
| KR (1) | KR20070047757A (enExample) |
| CN (1) | CN101076540B (enExample) |
| AT (1) | ATE455847T1 (enExample) |
| AU (1) | AU2005266543B2 (enExample) |
| BR (1) | BRPI0513855A (enExample) |
| CA (1) | CA2571426A1 (enExample) |
| DE (1) | DE602005019050D1 (enExample) |
| DK (1) | DK1771468T3 (enExample) |
| ES (1) | ES2340400T3 (enExample) |
| HR (1) | HRP20100227T1 (enExample) |
| IL (1) | IL180233A (enExample) |
| MX (1) | MX2007001152A (enExample) |
| NO (1) | NO20070956L (enExample) |
| NZ (1) | NZ552223A (enExample) |
| PL (1) | PL1771468T3 (enExample) |
| PT (1) | PT1771468E (enExample) |
| RS (1) | RS51381B (enExample) |
| RU (1) | RU2390558C2 (enExample) |
| SI (1) | SI1771468T1 (enExample) |
| WO (1) | WO2006010558A1 (enExample) |
| ZA (1) | ZA200701231B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0510886A (pt) * | 2004-06-18 | 2007-12-26 | Genentech Inc | método para aumentar a apoptose ou a citotoxicidade em células de mamìferos |
| DE102006020307A1 (de) * | 2006-05-03 | 2007-11-08 | Martin-Luther-Universität Halle-Wittenberg | TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung |
| WO2008142862A1 (ja) * | 2007-05-18 | 2008-11-27 | National University Corporation Asahikawa Medical College | 血管内皮前駆細胞の移植による抗がん療法 |
| CN102154213B (zh) * | 2011-01-19 | 2012-07-25 | 郑骏年 | 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞 |
| US20140369979A1 (en) * | 2012-02-01 | 2014-12-18 | Postech Academy-Industry Foundation | Vector simultaneously expressing dodecameric trail and hsv-tk suicide genes, and anticancer stem cell therapeutic agent using same |
| CN103288966B (zh) * | 2013-05-17 | 2015-01-21 | 华侨大学 | 一种融合受体及其用于治疗大肠癌的基因药物 |
| RU2552609C1 (ru) * | 2013-10-28 | 2015-06-10 | Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) | Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов |
| RU2716821C2 (ru) | 2014-10-24 | 2020-03-17 | Калиди Биотерапьютикс, Инк. | Комбинированный иммунотерапевтический подход к лечению рака |
| EP3971284B1 (en) * | 2015-07-29 | 2023-11-08 | ONK Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| US10906951B2 (en) | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| WO2019232631A1 (en) * | 2018-06-06 | 2019-12-12 | Stemcell Technologies Canada Inc. | Kits, compositions and methods for myeloid-derived suppressor cell enrichment |
| US12220465B2 (en) | 2018-11-28 | 2025-02-11 | Washington University | Compositions and methods for targeted treatment and imaging of cancer or tumors |
| WO2020188105A1 (en) | 2019-03-21 | 2020-09-24 | Onk Therapeutics Limited | Modified immune effector cells with increased resistance to cell death |
| EP3712257A1 (en) | 2019-03-21 | 2020-09-23 | ONK Therapeutics Limited | Modified natural killer cells with increased resistance to cell death |
| WO2021209625A1 (en) | 2020-04-17 | 2021-10-21 | Onk Therapeutics Limited | High potency natural killer cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5879672A (en) * | 1994-10-07 | 1999-03-09 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 1 |
| AU747602B2 (en) * | 1997-06-04 | 2002-05-16 | Oxford Biomedica (Uk) Limited | Vector |
| JP2004526666A (ja) * | 2000-09-11 | 2004-09-02 | マスク ファウンデーション フォー リサーチ デヴェロップメント | アポトーシスの選択的誘導によって腫瘍を治療するための組成物及び方法 |
| AU2001297677B2 (en) * | 2000-10-24 | 2007-07-05 | Immunex Corporation | Method for dendritic cells based immunotherapy of tumors using combination therapy |
| US7235358B2 (en) * | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| JP4493882B2 (ja) * | 2001-06-19 | 2010-06-30 | 株式会社カネカ | 抗原およびこの抗原を識別するモノクローナル抗体 |
-
2004
- 2004-07-29 EP EP04017907A patent/EP1621550A1/en not_active Withdrawn
-
2005
- 2005-07-21 SI SI200530969T patent/SI1771468T1/sl unknown
- 2005-07-21 HR HR20100227T patent/HRP20100227T1/hr unknown
- 2005-07-21 AU AU2005266543A patent/AU2005266543B2/en not_active Ceased
- 2005-07-21 WO PCT/EP2005/007957 patent/WO2006010558A1/en not_active Ceased
- 2005-07-21 DK DK05764208.4T patent/DK1771468T3/da active
- 2005-07-21 RU RU2007107369/13A patent/RU2390558C2/ru not_active IP Right Cessation
- 2005-07-21 AT AT05764208T patent/ATE455847T1/de active
- 2005-07-21 CA CA002571426A patent/CA2571426A1/en not_active Abandoned
- 2005-07-21 KR KR1020077000005A patent/KR20070047757A/ko not_active Ceased
- 2005-07-21 US US11/631,262 patent/US20070264231A1/en not_active Abandoned
- 2005-07-21 PT PT05764208T patent/PT1771468E/pt unknown
- 2005-07-21 JP JP2007522989A patent/JP5042826B2/ja not_active Expired - Fee Related
- 2005-07-21 MX MX2007001152A patent/MX2007001152A/es active IP Right Grant
- 2005-07-21 EP EP05764208A patent/EP1771468B1/en not_active Expired - Lifetime
- 2005-07-21 ES ES05764208T patent/ES2340400T3/es not_active Expired - Lifetime
- 2005-07-21 NZ NZ552223A patent/NZ552223A/en not_active IP Right Cessation
- 2005-07-21 RS RSP-2010/0179A patent/RS51381B/sr unknown
- 2005-07-21 BR BRPI0513855-8A patent/BRPI0513855A/pt not_active IP Right Cessation
- 2005-07-21 ZA ZA200701231A patent/ZA200701231B/xx unknown
- 2005-07-21 CN CN2005800324298A patent/CN101076540B/zh not_active Expired - Fee Related
- 2005-07-21 DE DE602005019050T patent/DE602005019050D1/de not_active Expired - Lifetime
- 2005-07-21 PL PL05764208T patent/PL1771468T3/pl unknown
-
2006
- 2006-12-21 IL IL180233A patent/IL180233A/en not_active IP Right Cessation
-
2007
- 2007-02-20 NO NO20070956A patent/NO20070956L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1771468A1 (en) | 2007-04-11 |
| BRPI0513855A (pt) | 2008-05-20 |
| ZA200701231B (en) | 2008-08-27 |
| RS51381B (sr) | 2011-02-28 |
| AU2005266543B2 (en) | 2012-02-02 |
| MX2007001152A (es) | 2007-04-18 |
| DE602005019050D1 (de) | 2010-03-11 |
| ES2340400T3 (es) | 2010-06-02 |
| IL180233A0 (en) | 2007-07-04 |
| JP5042826B2 (ja) | 2012-10-03 |
| RU2390558C2 (ru) | 2010-05-27 |
| US20070264231A1 (en) | 2007-11-15 |
| KR20070047757A (ko) | 2007-05-07 |
| DK1771468T3 (da) | 2010-05-25 |
| EP1771468B1 (en) | 2010-01-20 |
| SI1771468T1 (sl) | 2010-07-30 |
| CN101076540B (zh) | 2012-10-24 |
| WO2006010558A1 (en) | 2006-02-02 |
| IL180233A (en) | 2010-12-30 |
| WO2006010558A8 (en) | 2006-08-24 |
| AU2005266543A1 (en) | 2006-02-02 |
| RU2007107369A (ru) | 2008-09-10 |
| JP2008507961A (ja) | 2008-03-21 |
| NO20070956L (no) | 2007-02-20 |
| NZ552223A (en) | 2009-01-31 |
| CA2571426A1 (en) | 2006-02-02 |
| HRP20100227T1 (hr) | 2010-07-31 |
| CN101076540A (zh) | 2007-11-21 |
| ATE455847T1 (de) | 2010-02-15 |
| PT1771468E (pt) | 2010-04-20 |
| EP1621550A1 (en) | 2006-02-01 |
| HK1110874A1 (en) | 2008-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1771468T3 (pl) | Zasiedlające nowotwory komórki inżynierowane w celu wytwarzania ligandu czynnika martwicy nowotworu indukującego apoptozę (TRAIL) | |
| UY28926A1 (es) | Adenovirus quiméricos para uso en el tratamiento del cáncer | |
| EP4592314A3 (en) | Single-chain and multi-chain chimeric polypeptides and uses thereof | |
| Danielpour et al. | Cross-talk between IGF-I and TGF-β signaling pathways | |
| ZA202110393B (en) | Chimeric polypeptide assembly and methods of making and using the same | |
| AU2019415848A8 (en) | Claudin18.2 binding moieties and uses thereof | |
| MX2024010824A (es) | Moleculas de union contra bcma y usos de las mismas. | |
| CY1122833T1 (el) | Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7 | |
| CY1116970T1 (el) | Fkbp-l και χρησεις αυτων ως αναστολεις αγγειογενεσης | |
| MX2018006072A (es) | Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos. | |
| TW201613972A (en) | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof | |
| SG170080A1 (en) | Human monoclonal antibodies to o8e | |
| CR9907A (es) | Modulacion de la expresion del receptor de glucagon | |
| EA200970884A1 (ru) | Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18 | |
| DK1904102T3 (da) | ANTI-CCR7-receptorantistoffer til behandling af cancer | |
| DE602005007220D1 (de) | Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs | |
| EA200971067A1 (ru) | Триазолиламинопиримидиновые соединения | |
| MX2010006425A (es) | Moduladores de proteina cinasa de objetivos multiples 1,3-ciclopentadiona-substituida de cancer, angiogenesis y las trayectorias inflamatorias asociadas con los mismos. | |
| EP1968981A4 (en) | METHOD FOR TREATING TUMORS WITH AZAXANTHONES | |
| ATE529108T1 (de) | Zellmigrationsmodulierende verbindungen | |
| ATE512159T1 (de) | Cyclodipeptidsynthetasen und ihre verwendung zur synthese von cyclo(leu-leu)cyclodipeptid | |
| WO2004016810A3 (de) | Verwendung von an mrp4 bindenden substanzen zur diagnose und behandlung von krebserkrankungen | |
| ATE478894T1 (de) | Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept | |
| EA202092932A1 (ru) | Молекулы, связывающие bcma, и пути их применения | |
| EA202191821A1 (ru) | Группы, связывающие клаудин 18.2, и их использование |